Lilly Alimta To Be Available In Two Weeks Following Five-Month Review
This article was originally published in The Pink Sheet Daily
Executive Summary
Clinical trials show Alimta plus cisplatin has a three-month survival advantage over cisplatin alone. Lilly has submitted a supplemental application for treatment of second-line non-small cell lung cancer.